DBV Technologies (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "DBV Technologies" in English language version.

refsWebsite

Global rank English rank

6web.archive.org

1^st place

1^st place

2dbv-technologies.com

low place

low place

99^th place

77^th place

1businessweek.com

712^th place

526^th place

1fiercebiotech.com

low place

8,828^th place

1clinicaltrials.gov

5,225^th place

4,062^nd place

low place

low place

1ipdelivers.com

low place

low place

1evaluatepharma.com

low place

low place

1beyondallergy.com

low place

low place

1mtbeurope.info

low place

low place

1news-medical.net

8,069^th place

7,681^st place

1lundbeckfondventures.com

low place

low place

9,885^th place

7,892^nd place

low place

low place

14^th place

14^th place

low place

low place

1chicagochildrensresearch.org

low place

low place

1telegraph.co.uk

30^th place

24^th place

1globenewswire.com

2,614^th place

1,549^th place

archive.today

"DBV Technologies launches its third Viaskin® program, a first for the treatment of House Dust Mites (HDM) allergy in young children". Biotechnology Industry Organization. November 14, 2012. Archived from the original on April 14, 2013. Retrieved February 8, 2013.

beyondallergy.com

Heather Legg. "Peanut Allergy Patch". Beyond Allergy. Retrieved February 8, 2013.

bio.org

"DBV Technologies launches its third Viaskin® program, a first for the treatment of House Dust Mites (HDM) allergy in young children". Biotechnology Industry Organization. November 14, 2012. Archived from the original on April 14, 2013. Retrieved February 8, 2013.

bioworld.com

Marie Powers (January 16, 2013). "DBV Seeks Immunotherapeutic to Desensitize Food Allergies". BioWorld. Retrieved February 8, 2013.

bloomberg.com

"DBV Technologies SA". Bloomberg. Retrieved February 8, 2013.

businessweek.com

Albertina Torsoli (March 28, 2012). "Paris Is Europe Health IPO Hub With Most Sales in 20 Years". Bloomberg Businessweek. Archived from the original on March 31, 2012. Retrieved February 8, 2013.

chicagochildrensresearch.org

"Division of Allergy and Immunology" (PDF). Chicago Childrens Research. Retrieved February 8, 2013.

clinicaltrials.gov

"Efficacy and Safety of Several Doses of Viaskin Peanut in Adults and Children With Peanut Allergy (VIPES)". ClinicalTrials. Retrieved February 8, 2013.

dbv-technologies.com

"Presentation". DBV Technologies. Retrieved February 8, 2013.
"Management". DBV Technologies. Archived from the original on March 17, 2013. Retrieved February 8, 2013.

evaluatepharma.com

"DBV Technologies initiates VIPES phase IIb clinical study, the first global trial ever in desensitization of peanut-allergic children and adults". Evaluate Pharma. August 2, 2012. Retrieved February 8, 2013.

fiercebiotech.com

"DBV Technologies and Centre d'Immunologie de Marseille-Luminy (CIML) enter in a Collaboration Agreement". FierceBiotech. 17 October 2012. Retrieved February 8, 2013.

globenewswire.com

"DBV Technologies Announces Primary Endpoint Met in VIPES, Viaskin Peanut's Phase IIb Clinical Trial in Peanut Allergy". 22 September 2014. Archived from the original on 29 October 2014. Retrieved 28 October 2014.

ipdelivers.com

"Pierre-Henri Benhamou, DBV Technologies". Global Intellectual Property Center. Retrieved February 8, 2013.

lundbeckfondventures.com

"Successful Initial Public Offering (IPO) for DBV Technologies on the NYSE Euronext regulated market in Paris. DBV Technologies raises € 40.5 million". Lundbeckfond Ventures. March 28, 2012. Archived from the original on March 4, 2016. Retrieved February 8, 2013.

mtbeurope.info

"DBV Technologies closes $25.5m financing round". MTB Europe. February 7, 2011. Retrieved February 8, 2013.

news-medical.net

"DBV Technologies secures $25.5 million in Series C financing round". News Medical. January 5, 2011. Retrieved February 8, 2013.

nyse.com

"NYSE Euronext welcomes DBV Technologies to its European market". NYSE Euronext. March 29, 2012. Archived from the original on June 7, 2012. Retrieved February 8, 2013.

sofinnova.fr

"Sofinnova Partners' portfolio company DBV Technologies successfully raises €40.5M in its oversubscribed IPO". Sofinnova. March 29, 2012. Retrieved February 8, 2013.^{[permanent dead link‍]}

telegraph.co.uk

"Skin patch could cure peanut allergy". The Daily Telegraph. May 30, 2011. Archived from the original on June 1, 2011. Retrieved February 8, 2013.

web.archive.org

Albertina Torsoli (March 28, 2012). "Paris Is Europe Health IPO Hub With Most Sales in 20 Years". Bloomberg Businessweek. Archived from the original on March 31, 2012. Retrieved February 8, 2013.
"Management". DBV Technologies. Archived from the original on March 17, 2013. Retrieved February 8, 2013.
"Successful Initial Public Offering (IPO) for DBV Technologies on the NYSE Euronext regulated market in Paris. DBV Technologies raises € 40.5 million". Lundbeckfond Ventures. March 28, 2012. Archived from the original on March 4, 2016. Retrieved February 8, 2013.
"NYSE Euronext welcomes DBV Technologies to its European market". NYSE Euronext. March 29, 2012. Archived from the original on June 7, 2012. Retrieved February 8, 2013.
"Skin patch could cure peanut allergy". The Daily Telegraph. May 30, 2011. Archived from the original on June 1, 2011. Retrieved February 8, 2013.
"DBV Technologies Announces Primary Endpoint Met in VIPES, Viaskin Peanut's Phase IIb Clinical Trial in Peanut Allergy". 22 September 2014. Archived from the original on 29 October 2014. Retrieved 28 October 2014.